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Summary
A 58-year-old male presented with a history of two 
prior transient ischaemic attacks and was found to 
have a patent foramen ovale (PFO) in the absence of 
atrial fibrillation or relevant carotid atheromatosis. 
PFO closure was deferred at this stage due to the lack 
of clinical evidence. Three years later the patient was 
re-admitted after a major stroke with residual symp-
toms and finally underwent PFO closure in a mini-
mally invasive procedure using an Amplatzer PFO 
Occluder. 
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Case report
A 58-year-old mechanic actively involved in motocross 
racing was thrown off track four years prior when he 
experienced a transient left oro-facial palsy that spon-
taneously resolved within hours. A few months later 
these symptoms recurred accompanied by temporary 
motor aphasia and prompted hospitalisation. He ad-
mitted to casual smoking and had no significant past 
medical history except for a mildly elevated lipid pro-
file. Transoesophageal echocardiography identified 
>25 microbubbles (agitated saline) crossing the atrial 
septum and appearing in the left atrium within three 
heart cycles after a Valsalva manoeuver, consistent 
with a PFO grade III [1]. No atherosclerosis of the aor-
tic arch was documented. Atrial fibrillation was ruled 
out by in-hospital monitoring and an ambulatory 
Holter ECG, and Duplex ultrasound and transcranial 
Doppler studies revealed only minimal atheromatosis 
of the left carotid bifurcation. Screening for a hyperco-
agulable state was foregone because there was no per-
sonal or family history of venous thromboembolism. 
Again, the symptoms completely resolved within hours. 
Upon discharge smoking cessation 
was encouraged, antiplatelet ther-
apy with acetylsalicylic acid was 
initiated as a secondary prophy-
laxis and a statin was implemented 
for lipid control in accordance with 
current guidelines. The treating 
physician was reassuring the patient concerning the 
PFO and refrained from referral for closure. Three 
years later the patient returned to the emergency room 
with motoric aphasia that rapidly progressed to a hem-
isyndrome primarily with paralysis of the left upper 
extremity corresponding to a NIHSS score of 7/42. 
After intracranial haemorrhage was ruled out by com-
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Figure 1
Embolic occlusion of the right internal carotid artery on MRA.
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phy was consistent with the previous study showing 
a PFO grade III suggesting paradoxical embolism as 
the only obvious mechanism (fig. 2). There was no 
atrial septal aneurysm. According to the guidelines, 
the treating physician/neurologist switched  the anti-
platelet regimen from acetylsalicylic acid to clopidogrel 
as a secondary prevention and a follow-up carotid 
Duplex ultrasound with Doppler study was scheduled 
which was again consistent with minimal atherosclero-
sis. With respect to the PFO, conflicting recommenda-
tions were made by the treating physician and the 
cardiologist. While the first related the lack of a ran-
domised clinical trial that would dictate PFO closure in 
this setting, the latter convinced the patient with 
sound reasoning. 
In a minimally invasive outpatient procedure un-
der local anaesthesia the patent foramen ovale was 
crossed via the right femoral vein under fluoroscopic 
guidance and occluded using an Amplatzer PFO Oc-
cluder with a diameter of 25 mm (fig. 3). Adequate po-
sition of the device was confirmed prior to discharge by 
transthoracic echocardiography and a relevant resid-
ual shunt was ruled out. 
Discussion
The foramen ovale, an interatrial connection, is a pre-
requisite for the intrauterine circulation to bypass the 
immature lungs. It functionally closes after birth due 
to the subsequent decrease of right atrial pressure that 
sucks the septum premium against the septum secun-
dum. The prevalence of PFO declines with advancing 
age and is found in around one quarter of the popula-
tion during the fourth to eight decade of life. While 
asymptomatic in most people, the PFO harbours a risk 
of paradoxical embolism and has also been associated 
with migraine with aura, decompression illness in di-
vers, platypnoea-orthodeoxia syndrome, obstructive 
sleep apnoea, and high altitude oedema.
In up to 40% of cases the aetiology of an ischaemic 
stroke cannot be determined despite extensive work-up 
[2, 3]. Whereas case-control studies revealed a strong 
correlation between the presence of PFO and crypto-
genic stroke in adults aged <55 years, this relationship 
is still controversial in older age groups [4–9]. Even 
with medical treatment, patients with cryptogenic 
stroke with PFO are at increased risk for recurrence 
[10–13]. Whereas non-randomised data suggest an 
advantage of percutaneous PFO closure over medical 
treatment [14–17], a recent randomised trial compar-
ing PFO closure or medical therapy for cryptogenic 
stroke did not show a significant benefit with regard to 
a composite of stroke or TIA at two years of follow-up 
[18]. Longer follow-up is of essence in this realm.
Transfemoral closure of a PFO can be performed 
under local anaesthesia as a safe procedure with fa-
vourable long-term outcome [14, 16, 17]. The consider-
puted tomography intravenous thrombolysis with 
alteplase was started two hours after symptom onset. 
Magnetic resonance angiography identified a small 
cortical lesion in the right paracentral area as well as 
a delayed perfusion in the area of the middle cerebral 
artery and revealed a complete occlusion of the right 
internal carotid artery suggesting an embolic event 
(fig. 1). While speech was recovering steadily, residual 
fine motor skill disabilities of the left hand persisted. 
A 24-hour-ECG was repeated and again demonstrated 
regular sinus rhythm with no episodes of atrial fibril-
lation and a repeated transoesophageal echocardiogra-
Figure 2
Bubbles passing the PFO from the right (RA) to the left (LA) atrium on transoesoph-
ageal echocardiography.
Figure 3
Successful closure of the PFO with an Amplatzer PFO Occluder confirmed by 
contrast injection into the right atrium (RA) under fluoroscopy. 
LA = Left atrium.
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able risk of recurrent cerebrovascular accidents in pa-
tients with symptomatic PFO outweighted the infre-
quent occurrence of periinterventional complications 
mostly confined to the access site. Transcatheter clo-
sure of patent foramen ovale with significant right to 
left shunt can hence be recommended to patients suf-
fering from cryptogenic stroke based on common sense 
while awaiting randomised clinical trials in parallel to 
thorough evaluation of possible other sources of stroke.
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